Pages that link to "Q51570195"
Jump to navigation
Jump to search
The following pages link to Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. (Q51570195):
Displaying 50 items.
- ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Summary (Q22241786) (← links)
- Antihypertensive agents for preventing diabetic kidney disease (Q24202090) (← links)
- Calcium channel blockers versus other classes of drugs for hypertension (Q24236584) (← links)
- Calcium channel blockers versus other classes of drugs for hypertension (Q24240961) (← links)
- Comparison of calcium channel blockers with other classes of drugs for hypertension (Q24244886) (← links)
- Antihypertensive agents for preventing diabetic kidney disease (Q24245557) (← links)
- Standards of medical care in diabetes--2012 (Q24632533) (← links)
- Reporting on sex-based analysis in clinical trials of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker efficacy (Q24652838) (← links)
- (Q24806038) (← links)
- Diuretics: again the first step in the treatment of most patients with hypertension (Q24806951) (← links)
- Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials (Q26766599) (← links)
- Cardiovascular and Renal Outcomes of Renin-Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses (Q26767278) (← links)
- Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators (Q28144781) (← links)
- Prevention of coronary heart disease in diabetes (Q28183142) (← links)
- Optimizing the diabetic formulary: beyond aspirin and insulin (Q28193664) (← links)
- Drugs for cardiovascular risk reduction in the diabetic patient (Q28195413) (← links)
- Cardiovascular risk factors in diabetic patients with hypertension (Q28195415) (← links)
- Current concepts of cardiovascular diseases in diabetes mellitus (Q28196278) (← links)
- Amlodipine versus angiotensin II receptor blocker; control of blood pressure evaluation trial in diabetics (ADVANCED-J) (Q28200627) (← links)
- Approaches to prevention of cardiovascular complications and events in diabetes mellitus (Q28209964) (← links)
- Identifying and slowing progressive chronic renal failure (Q28344781) (← links)
- The effects of calcium channel blockers in the prevention of stroke in adults with hypertension: a meta-analysis of data from 273,543 participants in 31 randomized controlled trials (Q28487721) (← links)
- Hypertension-Related Morbidity and Mortality in African Americans?Why We Need to Do Better (Q29399489) (← links)
- Standards of medical care in diabetes--2013 (Q29620309) (← links)
- Effect of calcium channels blockers and inhibitors of the renin-angiotensin system on renal outcomes and mortality in patients suffering from chronic kidney disease: systematic review and meta-analysis. (Q30251636) (← links)
- The choice of antihypertensive drugs in patients with diabetes: angiotensin II and beyond (Q30310671) (← links)
- Why not prescribe the best drugs for hypertension now? (Q30333019) (← links)
- Hypertension management in patients with diabetic nephropathy (Q30433989) (← links)
- Should an angiotensin-converting enzyme inhibitor be standard therapy for patients with atherosclerotic disease? (Q31818207) (← links)
- Methods underpinning national clinical guidelines for hypertension: describing the evidence shortfall (Q33239013) (← links)
- Race and ethnicity in trials of antihypertensive therapy to prevent cardiovascular outcomes: a systematic review (Q33300205) (← links)
- Hypertension in the elderly (Q33545462) (← links)
- Standards of medical care in diabetes--2010. (Q33554238) (← links)
- ACE-inhibition and physical function: results from the Trial of Angiotensin-Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study. (Q33636677) (← links)
- Current status of calcium channel blockers in patients with cardiovascular disease (Q33642495) (← links)
- Blood pressure control, microalbuminuria and cardiovascular risk in Type 2 diabetes mellitus (Q33643752) (← links)
- Renal protection and antihypertensive drugs: current status (Q33649627) (← links)
- Calcium antagonists and safety: the turning of the tide (Q33691025) (← links)
- Drug treatment for hypertensive patients in special situations: diabetes and hypertension (Q33697713) (← links)
- Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus (Q33706621) (← links)
- Special considerations in the therapy of diabetic hypertension (Q33710484) (← links)
- Hypertension and diabetic retinopathy--what's the story? (Q33719166) (← links)
- Effects of the fixed combination of manidipine plus delapril in the treatment of hypertension inadequately controlled by monotherapy with either component: a phase III, multicenter, open-label, clinical trial (Q33738945) (← links)
- Understanding the quality chasm for hypertension control in diabetes: a structured review of "co-maneuvers" used in clinical trials (Q33750286) (← links)
- The treatment of hypertension and dyslipidemia in diabetes mellitus (Q33752800) (← links)
- Hypertension and diabetes: current issues (Q33762046) (← links)
- Long-term benefits of angiotensin II blockade: is the consensus changing? (Q33788387) (← links)
- Do pharmacologic differences among antihypertensive agents point to clinical benefits? (Q33788394) (← links)
- Management of hypertension. Ideal body weight is not realistic goal for lifestyle intervention (Q33799983) (← links)
- What are the elements of good treatment for hypertension? (Q33805317) (← links)